Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Feb 21, 2021 in Breast cancer | 0 comments

In a nutshell

This study investigated whether adding oral S-1 (Teysuno) to hormonal therapy improved outcomes in patients with estrogen receptor (ER)-positive and HER2-negative primary breast cancer (BC). The data showed that the combination of S-1 with hormonal therapy could be a potential treatment option for these patients.

Some background

BC is classified into different subtypes depending on the presence or absence of certain receptors (proteins found on the surface of the cancer cells). ER (female sex hormone receptor)-positive and HER2 negative is a subtype of BC that tests positive for the ER and negative for the HER2 protein. This type of cancer accounts for 70% of all BCs. Patients with this subtype of BC commonly receive hormonal treatment which acts by decreasing the female hormone estrogen.

Fluoropyrimidines (FP) are anti-cancer drugs. S-1 is an FP prescribed orally and has been shown to be effective in the treatment of BC. However, it is not known if adding S-1 to hormonal treatment improves outcomes in patients with ER+ HER2- BC.

Methods & findings

This study involved 1930 women with stage I-III ER+ HER2- invasive BC. 957 patients received S-1 plus hormonal therapy and 973 received hormonal therapy alone. The average follow-up time was 52.2 months.

87% of patients in the S-1 plus hormonal therapy group were alive after 5 years without signs of cancer compared with 82% in the hormonal therapy alone group. Cancer came back in other organs or tissues in 7% of the S-1 and hormonal therapy group compared to 10% of the hormonal therapy alone group.

31% of the S-1 group needed a reduction in the S-1 dose. The most common side effects were decreased white blood cells, diarrhea, and fatigue in both treatment groups.

The bottom line

This study concluded that the addition of oral S-1 to hormonal therapy improved the disease-free survival in patients with ER+ HER2- BC.

The fine print

A longer follow-up period is necessary to measure the overall survival with this treatment option. The study was sponsored by Taiho Pharmaceutical, the manufacturers of S-1.

Published By :

The Lancet. Oncology

Date :

Jan 01, 2021

Original Title :

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.

click here to get personalized updates